Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes

被引：0
作者：
Y. Jinnouchi
S. Yamagishi
M. Takeuchi
S. Ishida
Y. Jinnouchi
J. Jinnouchi
T. Imaizumi
机构：
[1] Kurume University School of Medicine,Department of Internal Medicine, Division of Cardio
[2] Hokuriku University,Vascular Medicine
[3] Ishida Clinic,Department of Pathophysiological Science
[4] Sasaguri Hospital,undefined
来源：
Clinical and Experimental Medicine | 2006年 / 6卷
关键词：
AGEs; Oxidative stress; Diabetes; Statin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 193
页数：2
相关论文
共 50 条
  • [1] Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes
    Jinnouchi, Y.
    Yamagishi, S.
    Takeuchi, M.
    Ishida, S.
    Jinnouchi, Y.
    Jinnouchi, J.
    Imaizumi, T.
    CLINICAL AND EXPERIMENTAL MEDICINE, 2006, 6 (04) : 191 - 193
  • [2] Elevated Serum Levels of Advanced Glycation End Products and their Monocyte Receptors in Patients with Type 2 Diabetes
    Su, Xu-dong
    Li, Shou-she
    Tian, Ya-qiang
    Zhang, Zhao-yan
    Zhang, Guang-zhen
    Wang, Le-xin
    ARCHIVES OF MEDICAL RESEARCH, 2011, 42 (07) : 596 - 601
  • [3] Relationship of serum advanced glycation end products with deterioration of periodontitis in type 2 diabetes patients
    Takeda, Munehiro
    Ojima, Miki
    Yoshioka, Hideo
    Inaba, Hiroaki
    Kogo, Mikihiko
    Shizukuishi, Satoshi
    Nomura, Makoto
    Amano, Atsuo
    JOURNAL OF PERIODONTOLOGY, 2006, 77 (01) : 15 - 20
  • [4] Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
    Yamagishi, Sho-ichi
    CURRENT DRUG TARGETS, 2011, 12 (14) : 2096 - 2102
  • [5] Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes
    Nakamura, Kazuo
    Yamagishi, Sho-ichi
    Adachi, Hisashi
    Matsui, Takanori
    Kurita-Nakamura, Yayoi
    Takeuchi, Masayoshi
    Inoue, Hiroyoshi
    Imaizumi, Tsutomu
    MICROVASCULAR RESEARCH, 2008, 76 (01) : 52 - 56
  • [6] Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes
    Takenaka, Katsuhiko
    Yamagishi, Sho-ichi
    Matsui, Takanori
    Nakamura, Kazuo
    Imaizumi, Tsutomu
    CURRENT NEUROVASCULAR RESEARCH, 2006, 3 (01) : 73 - 77
  • [7] Serum Levels of Advanced Glycation End Products (AGEs) are Independent Correlates of Insulin Resistance in Nondiabetic Subjects
    Tahara, Nobuhiro
    Yamagishi, Sho-ichi
    Matsui, Takanori
    Takeuchi, Masayoshi
    Nitta, Yoshikazu
    Kodama, Norihiro
    Mizoguchi, Minori
    Imaizumi, Tsutomu
    CARDIOVASCULAR THERAPEUTICS, 2012, 30 (01) : 42 - 48
  • [8] Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes
    Magdalena Kopytek
    Michał Ząbczyk
    Piotr Mazur
    Anetta Undas
    Joanna Natorska
    Cardiovascular Diabetology, 19
  • [9] Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes
    Nakamura, Kazuo
    Yamagishi, Sho-ichi
    Adachi, Hisashi
    Matsui, Takanori
    Kurita-Nakamura, Yayoi
    Takeuchi, Masayoshi
    Inoue, Hiroyoshi
    Imaizumi, Tsutomu
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2008, 24 (02) : 109 - 114
  • [10] Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes
    Kopytek, Magdalena
    Zabczyk, Michal
    Mazur, Piotr
    Undas, Anetta
    Natorska, Joanna
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
12345